gefitinib has been researched along with edatrexate in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (edatrexate) | Trials (edatrexate) | Recent Studies (post-2010) (edatrexate) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 117 | 34 | 2 |
| Protein | Taxonomy | gefitinib (IC50) | edatrexate (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Homo sapiens (human) | 0.0035 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.011 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0178 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
1 other study(ies) available for gefitinib and edatrexate
| Article | Year |
|---|---|
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |